The applicant appears in FDA 510(k) records from its Llanberis, Caernarfon, United Kingdom filing address, with product code DHB and Class II regulation 21 CFR 866.5750 for radioallergosorbent immunological test systems in the Immunology panel. Two traditional, non-third-party submissions were each decided substantially equivalent: K260331 on 4 September 2026 and K260400 on 2 November 2026. Both records list the same applicant name, and neither identifies a parent, brand owner or corporate affiliate. [1][2][4]

Peanut component and specific IgE filings

K260331 covers IMMULITE 2000 3gAllergy Specific IgE Vantage and IMMULITE 2000 Systems Peanut Allergen (F13). The FDA decision summary describes the submission purpose as a new device and the measurand as allergen-specific immunoglobulin E, with labeling supporting a substantial equivalence finding. K260400 covers IMMULITE 2000 nAra h 1, nAra h 3 and nAra h 6, received 6 February 2026 and decided 2 November 2026. [1][2][4]

Both filings were received in February 2026 and carry the same product code, regulation number and advisory committee, indicating a shared regulatory classification for the allergen IgE menu rather than separate device categories. [1][2]

Component-resolved testing context

A Siemens Healthineers peanut allergen specification sheet describes component-resolved diagnostics as measurement of IgE antibodies against individual peanut proteins, which the publisher states helps clinicians assess sensitization at the component level. The sheet lists peanut allergens including nAra h 1, rAra h 2, nAra h 3, nAra h 6, rAra h 8 and rAra h 9, and states that peanut allergy reactions range from mild itching to anaphylaxis. [6]

The same sheet reports agreement figures for those components against sample sets, with positive agreement between 94% and 100% and negative agreement between 90% and 100% across the listed allergens. These are publisher-reported method comparison results, not independent clinical validation. [6]

Instrument context and availability limits

Siemens Healthineers describes the IMMULITE 2000 immunoassay system as intended for medium- and high-volume laboratories, with throughput of up to 200 tests per hour and user-defined automatic dilution protocols. The IMMULITE 2000 XPi page describes menu consolidation and workload flexibility on a single analyzer. These are publisher statements about the instrument platforms, not FDA findings about the cleared assays. [7][8]

Siemens Healthineers pages carry availability qualifiers, including statements that certain products or features are not available for sale in the U.S., are for research use only in the U.S., or are under development, and that availability varies by country. Commercial availability of the specific cleared assays is not established by the public information. [7][8]

What the record collection shows

The supplied collection contains two linked 510(k) records, both with a substantially equivalent decision, and no recall records. The record sample comprises exactly those two entries, so the sample decision counts and the full collection decision counts are identical at two. These figures describe the supplied filings as of 20 November 2026 and are not measures of total portfolio size, sales or safety performance. [1][2]